Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 27 01 2020
pubmed: 6 6 2020
medline: 8 7 2021
entrez: 6 6 2020
Statut: epublish

Résumé

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010-2017. When outcomes from 2004 +/- 2009 and 2010-2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004-2009 and P <.0001 for 2010-2017), profression-free survival (P=.002 for 2004-2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers: NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.

Identifiants

pubmed: 32499241
pii: haematol.2020.248187
doi: 10.3324/haematol.2020.248187
pmc: PMC8168504
doi:

Banques de données

ClinicalTrials.gov
['NCT01527045', 'NCT01231412', 'NCT00793572', 'NCT00003954', 'NCT00003196', 'NCT00003145', 'NCT00005801', 'NCT00005803', 'NCT00005799', 'NCT01252667', 'NCT00006251', 'NCT00014235', 'NCT00027820', 'NCT00031655', 'NCT00036738', 'NCT00045435', 'NCT00052546', 'NCT00060424', 'NCT00075478', 'NCT00078858', 'NCT00089011', 'NCT00104858', 'NCT00105001', 'NCT00110058', 'NCT00397813']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1599-1607

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007093
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL122173
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL036444
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA078902
Pays : United States

Références

Blood. 2007 May 15;109(10):4557-63
pubmed: 17244684
Bone Marrow Transplant. 2002 May;29(9):777-82
pubmed: 12040476
Bone Marrow Transplant. 2016 Sep;51(9):1253-5
pubmed: 27088374
Br J Haematol. 2000 Dec;111(3):782-90
pubmed: 11122138
Haematologica. 2014 Oct;99(10):1624-31
pubmed: 25085357
J Clin Oncol. 2013 Jul 1;31(19):2437-49
pubmed: 23715573
Lancet Oncol. 2011 Dec;12(13):1195-203
pubmed: 21962393
Blood. 2007 Oct 1;110(7):2744-8
pubmed: 17595333
Blood. 2002 Sep 15;100(6):1977-83
pubmed: 12200355
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Blood. 2002 Feb 15;99(4):1159-64
pubmed: 11830461
Br J Haematol. 2016 Apr;173(1):96-104
pubmed: 26729448
Blood. 2016 Dec 22;128(25):2899-2908
pubmed: 27802969
J Clin Microbiol. 2004 Mar;42(3):1142-8
pubmed: 15004066
Bone Marrow Transplant. 2009 Jul;44(1):51-6
pubmed: 19139735
J Clin Oncol. 2007 Dec 1;25(34):5471-89
pubmed: 17909198
Leukemia. 2012 Mar;26(3):381-9
pubmed: 21886171
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Lifetime Data Anal. 2008 Dec;14(4):484-95
pubmed: 18791867
Leuk Lymphoma. 2019 Jul;60(7):1758-1766
pubmed: 30668198
Leuk Res. 2007 Feb;31(2):257-9
pubmed: 16620971
Cochrane Database Syst Rev. 2012 Jan 18;1:CD004386
pubmed: 22258955
Clin Infect Dis. 2005 Apr 15;40(8):1087-93
pubmed: 15791505
Blood. 2009 Mar 26;113(13):2888-94
pubmed: 19001082
Stat Med. 1999 Mar 30;18(6):695-706
pubmed: 10204198
J Clin Oncol. 2013 Jul 20;31(21):2662-70
pubmed: 23797000
Lancet Haematol. 2019 Aug;6(8):e409-e418
pubmed: 31248843
Br J Cancer. 2012 May 8;106(10):1626-37
pubmed: 22568999
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2017 Jul 13;130(2):221-228
pubmed: 28468799
Cancer Discov. 2016 Oct;6(10):1106-1117
pubmed: 27520294
Transplantation. 1998 Nov 27;66(10):1330-4
pubmed: 9846518
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
J Clin Oncol. 2013 Apr 20;31(12):1530-8
pubmed: 23478054
Kidney Int. 2005 Jan;67(1):272-7
pubmed: 15610251
Haematologica. 2019 Jun;104(6):1221-1229
pubmed: 30630975
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Intern Med. 2019 Apr;285(4):407-418
pubmed: 30372796
Blood. 2017 Aug 10;130(6):722-731
pubmed: 28588020
Clin Infect Dis. 2002 Apr 15;34(8):1094-7
pubmed: 11914998
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004386
pubmed: 16235360
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Leukemia. 2012 Nov;26(11):2353-9
pubmed: 22504140
Blood. 2008 Feb 15;111(4):2462-9
pubmed: 18056482
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
Ann Intern Med. 1992 Apr 15;116(8):624-9
pubmed: 1546861

Auteurs

Jason P Cooper (JP)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Barry E Storer (BE)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Noa Granot (N)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Boglark Gyurkocza (B)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Mohamed L Sorror (ML)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Thomas R Chauncey (TR)

Fred Hucthinson Cancer Research Center, Univ of Washington, VA Puget Sound Health Care, Seattle, USA.

Judith Shizuru (J)

Stanford University, Palo Alto, CA, USA.

Georg-Nikolaus Franke (GN)

University of Leipzig, Leipzig, Germany.

Michael B Maris (MB)

Colorado Blood Cancer Institute at HealthONE Presbyterian/St. Luke Medical Center, Denver, USA.

Michael Boyer (M)

University of Utah, Salt Lake City, UT, USA.

Benedetto Bruno (B)

Azienda Ospedaliera S Giovanni Battista, University of Turin, Turin, Italy.

Firoozeh Sahebi (F)

City of Hope/Kaiser Permanente Medical Group, Duarte, CA, USA.

Amelia A Langston (AA)

Winship Cancer Institute at Emory University, Atlanta, GA, USA.

Parameswaran Hari (P)

Medical College of Wisconsin, Milwaukee, WI, USA.

Edward D Agura (ED)

Baylor University, Dallas, TX, USA.

Søren Lykke Petersen (S)

University of Copenhagen Rigshospitalet, Copenhagen, Denmark.

Richard T Maziarz (RT)

Oregon Health and Science University, Portland, OR, USA.

Wolfgang Bethge (W)

Medical Center University of Tübingen, Tübingen, Germany.

Julie Asch (J)

LDS Hospital, Salt Lake City, UT, USA.

Jonathan A Gutman (JA)

University of Colorado, Denver, CO, USA.

Gitte Olesen (G)

Aarhus University, Aarhus, Denmark.

Andrew M Yeager (AM)

University of Arizona Cancer Center, Tucson, AZ, USA.

Kai Hübel (K)

University Hospital of Cologne, Cologne, Germany.

William J Hogan (WJ)

Mayo Clinic, Rochester, MN, USA.

David G Maloney (DG)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Marco Mielcarek (M)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Paul J Martin (PJ)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Mary E D Flowers (MED)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

George E Georges (GE)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Ann E Woolfrey (AE)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Joachim H Deeg (JH)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Bart L Scott (BL)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

George B McDonald (GB)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Rainer Storb (R)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Brenda M Sandmaier (BM)

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH